Servier, an international pharmaceutical company, completed the acquisition of Symphogen, a privately-owned biotech company focused on oncology and immuno-oncology, from Novo, EW Healthcare Partners, Sunstone and Gilde Healthcare. Financial terms were not disclosed. "The completion of this acquisition enables Servier to boost its antibody capabilities in oncology and its other therapeutic areas. The efficient antibody discovery and research platform of Symphogen will strengthen our R&D capabilities and pipeline in line with our aim of making life-saving treatments available to more patients across the world," Claude Bertrand, Servier Executive Vice-President Research & Development.